A single dose of ORK1 generated durable disease control in two independent inflammatory bowel disease mouse models ORK1 induced sustained myeloid reprogramming, regulating chronic inflammationThis ...
In a first-of-its-kind clinical trial, UCLA scientists have shown it's possible to reprogram a patient's blood-forming stem cells to generate a continuous supply of functional T cells, the immune ...
In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the "recipe" for the transformation. Researchers at Lund University have now created ...
MIT researchers have engineered ligand-directed lipid nanoparticles that reprogram natural killer cells into CAR-bearing ...
SAN CARLOS, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, today announced the ...
Efficacy and safety of chidamide in combination with serplulimab and standard third-line treatments in advanced colorectal cancer: A single arm, exploratory phase 2 trial. This is an ASCO Meeting ...
Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics for solid tumors, announced the close of its seed financing round, bringing the company’s total ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results